# EDGAR Filing Document

**Accession Number:** 0002029039
**File Stem:** 0000000000-26-002335
**Filing Date:** 2026-3
**Character Count:** 2087
**Document Hash:** 5f9c6bf56fd4128ee567718b1be86dcb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-002335.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0000000000-26-002335

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260306

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nasus Pharma Ltd
- **CENTRAL INDEX KEY:** 0002029039
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 516022712
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-293950

**BUSINESS ADDRESS:**
- **STREET 1:** 29 HARAKEVET ST
- **CITY:** TEL AVIV - YAFO
- **STATE:** L3
- **ZIP:** 6618003
- **BUSINESS PHONE:** 972 54-255-3956

**MAIL ADDRESS:**
- **STREET 1:** 29 HARAKEVET ST
- **CITY:** TEL AVIV - YAFO
- **STATE:** L3
- **ZIP:** 6618003
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-26-008581

## Text-Extract

```

                                                           March 6, 2026

Dan Teleman
Chief Executive Officer
Nasus Pharma Ltd
P.O. Box 284
Tel Aviv, Israel 6100201

       Re: Nasus Pharma Ltd
           Registration Statement on Form F-1
           Filed March 2, 2026
           File No. 333-293950
Dear Dan Teleman:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Jimmy McNamara at 202-551-7349 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._